We analyzed the clinicopathological, cytogenetic, and molecular features of 18 primary cuta-neous diffuse large B-cell lymphomas (PCDLBCLs) and 15 DLBCLs secondarily localized to the skin (SCDLBCLs), highlighting biological similarities and differences between the 2 groups.PCDLBCLs were subclassified after histopathological review as PCDLBCL-leg type (PCDLBCL-LT, 10 cases) and the PCDLBCL-not otherwise specified (PCDLBCL-NOS, 8 cases). Immunohisto-chemistry for Hans' algorithm markers, BCL2, and MYC was performed. The molecular study included the determination of the cell of origin (COO) by Lymph2Cx assay on NanoString platform, FISH analysis of IgH, BCL2, BCL6, and MYC genes, as well as the mutation analysis of MYD88 gene.In immunohistochemistry analysis, BCL2 and MYC hyperexpression was more frequent in LT than in NOS cases and, according to Hans' algorithm, PCDLBCL-LTs were mostly of the non-GC type (8/ 10), whereas in PCDLBCL-NOS, the GC type prevailed (6/8). The determination of COO using Lymph2Cx supported and further confirmed these results. In FISH analysis, all but one LT cases versus 5 of 8 PCDLBCL-NOS showed at least one gene rearrangement among IgH, BCL2, MYC, or BCL6. In addition, MYD88 mutations were more frequently present in LT than in NOS subtypes. Interestingly, MYD88-mutated patients were older, with a non-GC phenotype and had worse OS, compared to MYD88 WT cases. Overall, SCDLBCL did not show, at the genetic and expression level, different pro-files than PCDLBCL, even if they bear a significantly worse prognosis. At survival analysis, the most important prognostic factors in patients with PCDLBCL were age and MYD88 mutation, whereas relapse and high Ki-67 expression were relevant in patients with SCDLBCL.Our study comprehensively analyzed the clinicopathological and molecular features of PCDLBCL-LT, PCDLBCL-NOS, and SCDLBCL, underlining the differences among them and the importance of properly identifying these entities at the time of diagnosis.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas / Uccella, Silvia; Goteri, Gaia; Maiorana, Antonino; Donati, Valentina; Tibiletti, Maria Grazia; Magnoli, Francesca; Facchi, Sofia; Merchiori, Deborah; Morsia, Erika; Papotti, Robel; Bettelli, Stefania; Forti, Elisa; Galimberti, Sara; Rupoli, Serena; Filosa, Alessandra; Dardanis, Dimitri; Bomben, Riccardo; Braglia, Luca; Pozzi, Samantha; Sacchi, Stefano. - In: HUMAN PATHOLOGY. - ISSN 0046-8177. - 136:(2023), pp. 44-55. [10.1016/j.humpath.2023.03.012]

Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas

Maiorana, Antonino;Donati, Valentina;Papotti, Robel;Bettelli, Stefania;Forti, Elisa;Galimberti, Sara;Bomben, Riccardo;Braglia, Luca;Pozzi, Samantha;Sacchi, Stefano
2023

Abstract

We analyzed the clinicopathological, cytogenetic, and molecular features of 18 primary cuta-neous diffuse large B-cell lymphomas (PCDLBCLs) and 15 DLBCLs secondarily localized to the skin (SCDLBCLs), highlighting biological similarities and differences between the 2 groups.PCDLBCLs were subclassified after histopathological review as PCDLBCL-leg type (PCDLBCL-LT, 10 cases) and the PCDLBCL-not otherwise specified (PCDLBCL-NOS, 8 cases). Immunohisto-chemistry for Hans' algorithm markers, BCL2, and MYC was performed. The molecular study included the determination of the cell of origin (COO) by Lymph2Cx assay on NanoString platform, FISH analysis of IgH, BCL2, BCL6, and MYC genes, as well as the mutation analysis of MYD88 gene.In immunohistochemistry analysis, BCL2 and MYC hyperexpression was more frequent in LT than in NOS cases and, according to Hans' algorithm, PCDLBCL-LTs were mostly of the non-GC type (8/ 10), whereas in PCDLBCL-NOS, the GC type prevailed (6/8). The determination of COO using Lymph2Cx supported and further confirmed these results. In FISH analysis, all but one LT cases versus 5 of 8 PCDLBCL-NOS showed at least one gene rearrangement among IgH, BCL2, MYC, or BCL6. In addition, MYD88 mutations were more frequently present in LT than in NOS subtypes. Interestingly, MYD88-mutated patients were older, with a non-GC phenotype and had worse OS, compared to MYD88 WT cases. Overall, SCDLBCL did not show, at the genetic and expression level, different pro-files than PCDLBCL, even if they bear a significantly worse prognosis. At survival analysis, the most important prognostic factors in patients with PCDLBCL were age and MYD88 mutation, whereas relapse and high Ki-67 expression were relevant in patients with SCDLBCL.Our study comprehensively analyzed the clinicopathological and molecular features of PCDLBCL-LT, PCDLBCL-NOS, and SCDLBCL, underlining the differences among them and the importance of properly identifying these entities at the time of diagnosis.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2023
136
44
55
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas / Uccella, Silvia; Goteri, Gaia; Maiorana, Antonino; Donati, Valentina; Tibiletti, Maria Grazia; Magnoli, Francesca; Facchi, Sofia; Merchiori, Deborah; Morsia, Erika; Papotti, Robel; Bettelli, Stefania; Forti, Elisa; Galimberti, Sara; Rupoli, Serena; Filosa, Alessandra; Dardanis, Dimitri; Bomben, Riccardo; Braglia, Luca; Pozzi, Samantha; Sacchi, Stefano. - In: HUMAN PATHOLOGY. - ISSN 0046-8177. - 136:(2023), pp. 44-55. [10.1016/j.humpath.2023.03.012]
Uccella, Silvia; Goteri, Gaia; Maiorana, Antonino; Donati, Valentina; Tibiletti, Maria Grazia; Magnoli, Francesca; Facchi, Sofia; Merchiori, Deborah; ...espandi
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0046817723000722-main.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.03 MB
Formato Adobe PDF
1.03 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1337310
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact